Research Progress on Postoperative Adjuvant Therapy for Completely Resected Stage ⅠB Non-small Cell Lung Cancer
10.3971/j.issn.1000-8578.2023.22.0933
- VernacularTitle:ⅠB期非小细胞肺癌完全切除术后辅助治疗方式的研究进展
- Author:
Shishi MA
1
;
Yuran DAI
;
Xiaopin CHEN
Author Information
1. Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
- Publication Type:Research Article
- Keywords:
Non-small cell lung cancer;
Adjuvant chemotherapy;
Targeted therapy;
Immunotherapy;
Prognostic factors
- From:
Cancer Research on Prevention and Treatment
2023;50(3):303-308
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is considered as the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about 85% of primary lung cancer. Owing to the improved utilization of medical technological level and the popularization of health examinations, the detection rate of early-stage NSCLC is gradually increasing. The main treatment modalities for early-stage NSCLC are surgical resection and adjuvant chemotherapy. Platinum-based chemotherapy is recommended as the standard postoperative adjuvant treatment for patients with completely resected stageⅡ-ⅢA NSCLC. However, adjuvant therapy remains a controversial option in stageⅠB NSCLC. This review focuses on postoperative adjuvant therapy such as adjuvant chemotherapy, targeted therapy, and immunotherapy for completely resected stageⅠB NSCLC. Moreover, the biomarkers and prognostic factors of high-risk patients are discussed.
